Personalis, Inc. (@PersonalisInc) / X

Personalis, Inc.

1,240 posts

Personalis, Inc.

@PersonalisInc

Fremont, CA

personalis.com

Joined September 2011

Personalis, Inc.
@PersonalisInc
Sep 14, 2024
Insightful talk from one of our collaborators, @CharlesSwanton, at #ESMO24 who highlighted new post-surgical monitoring data from the groundbreaking TRACERx study, one of the most robust ctDNA studies for early-stage NSCLC. Visit us at booth # 509 at ESMO to learn more.
2.1K
Personalis, Inc.
@PersonalisInc
Feb 10, 2025
- Pre-surgical detection for patients with no prior therapy was 93.5% - Detection of ctDNA during landmark analysis (weeks 4 and 8) was highly associated with clinical recurrence - NeXT Personal detected MRD for all patients prior to disease recurrence - 64.3% of recurrences were
00:00
1.3K
Personalis, Inc.
@PersonalisInc
Apr 22, 2025
🚨 BIG NEWS! 🚨 Our NeXT Personal® ultrasensitive ctDNA assay will be featured at #AACR25 in Chicago! 🌟 Two oral presentations: 🔬 Dr. @emma_titmuss presents #VICTORI study (colorectal #MRD) - Apr 28, 3:35PM, S105 🧬 Prof. @CharlesSwanton shares #TRACERx results - Apr 28,
00:00
2.7K
Personalis, Inc.
@PersonalisInc
Oct 6, 2022
ICYMI: Tumor-informed #LiquidBiopsies (TILBs) utilizing whole genome sequencing (#WGS) have the potential to accelerate #DrugDevelopment and improve trial success rates. See our article in @GENbio to find out more: bit.ly/3esk1PL.
Tumor-Informed Liquid Biopsies to Transform Oncology Drug Development
From genengnews.com
Personalis, Inc.
@PersonalisInc
Jan 21, 2025
Last week, we published new data 📊 in Nature Medicine highlighting TRACERx lung cancer study pre-operative ctDNA results with NeXT Personal®: - 81% sensitivity for lung adenocarcinoma (LUAD) and 100% for non-LUAD - LUAD patients who were ctDNA-negative preoperatively achieved
3.1K
Personalis, Inc.
@PersonalisInc
Mar 3, 2025
Our groundbreaking data in #BreastCancer was just published in the ESMO Annals of Oncology! (@myESMO). In collaboration with @royalmarsdenNHS and @ICR_London (@igmurillas), this study reports on the performance of NeXT Personal® in a cohort of 78 patients with breast cancer (all
00:00
2.5K
Personalis, Inc.
@PersonalisInc
Jan 13, 2025
Today, we published new results from the #TRACERx lung cancer study in Nature Medicine: bit.ly/40wMHww In collaboration with @CharlesSwanton and his colleagues at @TheCrick and @uclcancer, this groundbreaking study highlights advancements in #LungCancer detection using
00:00
2.3K
Personalis, Inc.
@PersonalisInc
Jan 24, 2025
We’re here along with our collaborators at ASCO #GI25 in the Moscone Center in downtown San Francisco! We’re excited to highlight a few posters with data in #ColorectalCancer, including results from the VICTORI study using NeXT Personal® in collaboration with @BCCancer (Dr
00:00
1.7K
Personalis, Inc.
@PersonalisInc
Jan 16, 2024
Today we announced that we received a final Medicare coverage determination for our NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries: bit.ly/48ZGril #PrecisionOncology
00:00
4.3K
Personalis, Inc.
@PersonalisInc
Apr 29, 2025
🚨 BIG NEWS! 🚨 We showed strong results from the VICTORI study at #AACR25 (@emma_titmuss, @BCCancer), which utilized our ultrasensitive NeXT Personal® assay in detecting early signs of residual or recurrent in a cohort of 71 patients with resectable stage I-IV #ColorectalCancer
00:00
1.9K
Personalis, Inc.
@PersonalisInc
May 20, 2025
“Cancer does not define me, but it is a part of who I am. It is a part of my story. This is Mary 2.0. Now’s my second chance.” We’re incredibly honored to share Mary Royal’s story as a breast cancer survivor, and how our NeXT Personal® circulating tumor DNA (ctDNA) test gave
00:00
2K
Personalis, Inc.
@PersonalisInc
Mar 29, 2023
This week, several of the latest Illumina NovaSeq X sequencers arrived at Personalis. Our team is excited to get these running and generating data for patients and partners! Learn more about how we innovate: bit.ly/3lVpJ0z. #PrecisionOncology #Genomics
2.4K
Personalis, Inc.
@PersonalisInc
Aug 25, 2021
Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development, bit.ly/3DjjRBZ
Personalis, Inc.
@PersonalisInc
May 6, 2025
📑 NEW ARTICLE in @GenomeWeb! Check out the latest article which highlights our amazing new data presented during #AACR25. • VICTORI study: demonstrated the value of our ultrasensitive #MRD platform in #ColorectalCancer. • #TRACERx study: further research showed that
1.7K